308 related articles for article (PubMed ID: 25313010)
21. Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells.
Leon LG; Gemelli M; Sciarrillo R; Avan A; Funel N; Giovannetti E
Curr Drug Targets; 2014; 15(14):1331-40. PubMed ID: 25483224
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J
Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162
[TBL] [Abstract][Full Text] [Related]
23. The compound millepachine and its derivatives inhibit tubulin polymerization by irreversibly binding to the colchicine-binding site in β-tubulin.
Yang J; Yan W; Yu Y; Wang Y; Yang T; Xue L; Yuan X; Long C; Liu Z; Chen X; Hu M; Zheng L; Qiu Q; Pei H; Li D; Wang F; Bai P; Wen J; Ye H; Chen L
J Biol Chem; 2018 Jun; 293(24):9461-9472. PubMed ID: 29691282
[TBL] [Abstract][Full Text] [Related]
24. A Novel Nitrobenzoate Microtubule Inhibitor that Overcomes Multidrug Resistance Exhibits Antitumor Activity.
Zheng YB; Gong JH; Liu XJ; Wu SY; Li Y; Xu XD; Shang BY; Zhou JM; Zhu ZL; Si SY; Zhen YS
Sci Rep; 2016 Aug; 6():31472. PubMed ID: 27510727
[TBL] [Abstract][Full Text] [Related]
25. Quinolin-6-Yloxyacetamides Are Microtubule Destabilizing Agents That Bind to the Colchicine Site of Tubulin.
Sharma A; Sáez-Calvo G; Olieric N; de Asís Balaguer F; Barasoain I; Lamberth C; Díaz JF; Steinmetz MO
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28640209
[TBL] [Abstract][Full Text] [Related]
26. Targeted therapies: Tivantinib--a cytotoxic drug in MET inhibitor's clothes?
Michieli P; Di Nicolantonio F
Nat Rev Clin Oncol; 2013 Jul; 10(7):372-4. PubMed ID: 23712183
[No Abstract] [Full Text] [Related]
27. Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines.
Calles A; Kwiatkowski N; Cammarata BK; Ercan D; Gray NS; Jänne PA
Mol Oncol; 2015 Jan; 9(1):260-9. PubMed ID: 25226813
[TBL] [Abstract][Full Text] [Related]
28. Discovery of Novel Quinoline-Chalcone Derivatives as Potent Antitumor Agents with Microtubule Polymerization Inhibitory Activity.
Li W; Xu F; Shuai W; Sun H; Yao H; Ma C; Xu S; Yao H; Zhu Z; Yang DH; Chen ZS; Xu J
J Med Chem; 2019 Jan; 62(2):993-1013. PubMed ID: 30525584
[TBL] [Abstract][Full Text] [Related]
29. The novel tubulin polymerization inhibitor MHPT exhibits selective anti-tumor activity against rhabdomyosarcoma in vitro and in vivo.
Mu Y; Liu Y; Li L; Tian C; Zhou H; Zhang Q; Yan B
PLoS One; 2015; 10(3):e0121806. PubMed ID: 25811876
[TBL] [Abstract][Full Text] [Related]
30. CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells.
Dinić J; Ríos-Luci C; Karpaviciene I; Cikotiene I; Fernandes MX; Pešić M; Padrón JM
Invest New Drugs; 2020 Jun; 38(3):584-598. PubMed ID: 31177401
[TBL] [Abstract][Full Text] [Related]
31. Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown.
Previdi S; Abbadessa G; Dalò F; France DS; Broggini M
Mol Cancer Ther; 2012 Jan; 11(1):214-23. PubMed ID: 22027690
[TBL] [Abstract][Full Text] [Related]
32. DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells.
Podolski-Renić A; Banković J; Dinić J; Ríos-Luci C; Fernandes MX; Ortega N; Kovačević-Grujičić N; Martín VS; Padrón JM; Pešić M
Eur J Pharm Sci; 2017 Jul; 105():159-168. PubMed ID: 28502672
[TBL] [Abstract][Full Text] [Related]
33. 6α-Acetoxyanopterine: A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer Cells.
Levrier C; Sadowski MC; Rockstroh A; Gabrielli B; Kavallaris M; Lehman M; Davis RA; Nelson CC
Mol Cancer Ther; 2017 Jan; 16(1):3-15. PubMed ID: 27760837
[TBL] [Abstract][Full Text] [Related]
34. Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.
Loganzo F; Hari M; Annable T; Tan X; Morilla DB; Musto S; Zask A; Kaplan J; Minnick AA; May MK; Ayral-Kaloustian S; Poruchynsky MS; Fojo T; Greenberger LM
Mol Cancer Ther; 2004 Oct; 3(10):1319-27. PubMed ID: 15486199
[TBL] [Abstract][Full Text] [Related]
35. IMB5476, a novel microtubule inhibitor, induces mitotic catastrophe and overcomes multidrug resistance in tumors.
Zheng YB; Dong YQ; Si SY; Zhen YS; Gong JH
Eur J Pharmacol; 2022 Mar; 919():174802. PubMed ID: 35143830
[TBL] [Abstract][Full Text] [Related]
36. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
Wong VK; Chiu P; Chung SS; Chow LM; Zhao YZ; Yang BB; Ko BC
Clin Cancer Res; 2005 Aug; 11(16):6002-11. PubMed ID: 16115945
[TBL] [Abstract][Full Text] [Related]
37. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
Kuo CC; Hsieh HP; Pan WY; Chen CP; Liou JP; Lee SJ; Chang YL; Chen LT; Chen CT; Chang JY
Cancer Res; 2004 Jul; 64(13):4621-8. PubMed ID: 15231674
[TBL] [Abstract][Full Text] [Related]
38. Tivantinib (ARQ-197) exhibits anti-tumor activity with down-regulation of FAK in oral squamous cell carcinoma.
Xi WH; Yang LY; Cao ZY; Qian Y
Biochem Biophys Res Commun; 2015 Feb; 457(4):723-9. PubMed ID: 25623532
[TBL] [Abstract][Full Text] [Related]
39. Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence.
Zhu C; Zuo Y; Wang R; Liang B; Yue X; Wen G; Shang N; Huang L; Chen Y; Du J; Bu X
J Med Chem; 2014 Aug; 57(15):6364-82. PubMed ID: 25061803
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological evaluation of novel benzo[c]acridine-diones as potential anticancer agents and tubulin polymerization inhibitors.
Behbahani FS; Tabeshpour J; Mirzaei S; Golmakaniyoon S; Tayarani-Najaran Z; Ghasemi A; Ghodsi R
Arch Pharm (Weinheim); 2019 Jun; 352(6):e1800307. PubMed ID: 31012156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
